AdJane annonce la première validation clinique de sa plateforme de vaccins OMV induisant une immunité muqueuse chez l'humain

Phase 1positiveOMV vaccine platformPositive

AI Analysis

Summary

AdJane announced first clinical validation of its OMV vaccine platform demonstrating mucosal immunity induction in humans from Phase 1 results, supporting development programs in pandemic preparedness, respiratory infectious diseases, and antimicrobial resistance.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

First clinical validation of OMV vaccine platform demonstrating mucosal immunity induction in humans

Importance:6/10

Sentiment:

0.75

vaccinePhase_1_dataplatform_validationmucosal_immunitypandemic_preparedness

Read the original article

Published by PR Newswire Biotech on July 3, 2026 8:00 AM

Read Original